These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9796964)

  • 41. Folate status in patients receiving maintenance doses of sulfasalazine.
    Longstreth GF; Green R
    Arch Intern Med; 1983 May; 143(5):902-4. PubMed ID: 6148048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of malignant effusions on methotrexate disposition.
    Li J; Gwilt P
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):373-82. PubMed ID: 12439595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
    Ferry DR; Smith A; Malkhandi J; Fyfe DW; deTakats PG; Anderson D; Baker J; Kerr DJ
    Clin Cancer Res; 1996 Apr; 2(4):659-68. PubMed ID: 9816216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A long-term study of the absorption of large oral doses of folic acid.
    Zettner A; Boss GR; Seegmiller JE
    Ann Clin Lab Sci; 1981; 11(6):516-24. PubMed ID: 7325593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
    Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
    Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of lithium in human plasma and erythrocytes.
    Poust RI; Mallinger AG; Mallinger J; Himmelhoch JM; Hanin I
    Psychopharmacol Commun; 1976; 2(2):91-103. PubMed ID: 981712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
    Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection.
    Synold TW; Xi B; Newman EM; Muggia FM; Doroshow JH
    J Chromatogr B Biomed Appl; 1996 Aug; 683(2):245-9. PubMed ID: 8891922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
    Budman DR; Johnson R; Barile B; Bowsher RR; Vinciguerra V; Allen SL; Kolitz J; Ernest CS; Kreis W; Zervos P; Walling J
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):525-31. PubMed ID: 11459206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets.
    Pohland RC; Alati T; Lantz RJ; Grindey GB
    J Pharm Sci; 1994 Oct; 83(10):1396-9. PubMed ID: 7884657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Competitive particle concentration fluorescence immunoassay for measuring 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) in serum.
    Taber LD; O'Brien P; Bowsher RR; Sportsman JR
    Clin Chem; 1991 Feb; 37(2):254-60. PubMed ID: 1993335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.
    Turner RN; Aherne GW; Curtin NJ
    Br J Cancer; 1997; 76(10):1300-7. PubMed ID: 9374375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.